RT @RecursionPharma: Join us live for our Update Call today, 11/20 at: ⏰ 5:30am MT ⏰ 7:30am ET ⏰ 12:30pm GMT Submit your questions at…

Our business combination with @RecursionPharma is officially closed and one TechBio powerhouse has emerged. Our expanded clinical pipeline, advanced preclinical programs, and partnership programs puts us on par with many mid-sized pharma companies. Meanwhile, our combined platforms – bringing together the best of digital biology and chemistry with the industry’s fastest supercomputer – will allow us to rapidly iterate and scale. 🔹Highlights: ▫️Pipeline: 10 clinical and preclinical and 10 advanced discovery programs across rare disease, infectious disease, and oncology – an unprecedented scale achievable only through the speed and efficiency brought by our combined AI-enabled platforms. ▫️Partnerships: More than 10 partnered programs with Sanofi, Roche and Genentech, Bayer, and Merck KGaA, Darmstadt, Germany with $450 million in upfront and milestone payments already received & which could yield over $20 billion in additional milestones before royalties. ▫️Platform: Combining Maps of Biology driven by 60+ petabytes of proprietary data, automated labs, supercomputing & ML models with precision chemistry capabilities to design & test highly optimized first-in-class molecules for high-interest targets. 🔹How We’re Improving Pharma Averages: ▫️3X Speed: Traditional pharma takes 30 months to develop a validated lead candidate; we’re doing it in as little as 10 months. ▫️10X Productivity: Traditional pharma produces 2,500 molecules before they find a compound for testing; we’re producing just 250 on average. ▫️Up to 80% Cost Reduction: Traditional pharma costs $25-$35 million to reach IND, we’re getting there for $5-$10 million. 👉Learn more: 👉Follow Recursion at: @RecursionPharma

On Nov. 20, join the call! On Nov. 13, we announced that Exscientia & @RecursionPharma shareholders have approved the proposed business combination. On Wed., Nov. 20, 7:30am ET, 5:30am MT, 12:30pm GMT, we’re holding a special update call to discuss the next chapter after the planned close of our business combination. This is a pivotal moment for the TechBio industry – bringing together two industry-leading pipelines, significant therapeutic discovery partnerships with leading pharma companies, and automated, AI-enabled platforms in biology & chemistry. 🔹The update call will be livestreamed on X here: or join us on: ▫️LinkedIn: ▫️YouTube: 👉Submit your questions here either prior to – or during – the livestream: 👉Learn more:

Don’t miss @drrichjlaw our Chief Business Officer, presenting at the @UK_ASF next week! Rich will give an overview on the role of AI, automation and partnerships in drug discovery at Exscientia. Learn more about the event here:

Checkout our poster at #ENASymp24 today to learn about Xcellomics - a collaboration between Exscientia and @UniofOxford with the mission to accelerate the translation of novel biological discoveries into cancer drug candidates. Learn more:

Download our #ENASymp24 poster highlighting the latest data for our LSD1 inhibitor, showcasing the identification of PD biomarkers related to ‘539 treatment, as well as ‘539 efficacy in a preclinical AML model with limited impact on platelet levels. $EXAI

Download our #ENASymp24 poster highlighting the latest preclinical data for our MALT1 inhibitor EXS73565, detailing the combination potential for MALT1 and BTK inhibitors in B-cell malignancies $EXAI

We’re delighted to announce that we’ve achieved milestones for two programmes in our @sanofi collaboration, for which we’ll receive an aggregate of $15 million and are eligible for over $600 million in additional milestone payments. Learn more: $EXAI

Interesting article from @GENbio including Thorsten Nowak, our VP MedChem's thoughts, on how coupling predictive modelling, automated experimentation & a multiparametric approach to drug design allows us to find potentially better drugs, more efficiently

We’re excited to announce that we’ll be presenting new preclinical data for both our LSD1 and MALT1 inhibitors at the upcoming ENA Symposium. Learn more here: #drugdiscovery #oncology #ENASymp24 $EXAI

We’re delighted that Nikolaus Krall, EVP Precision Medicine, has been named as an inspiring leader in the @PharmaVoice 100 list. Nikolaus has been instrumental in the advancement of patient-first AI and the precision medicine platform at Exscientia

Download our #BostonDOT24 poster to explore the automation of a cellular biosensor assay to allow for efficient hit compound screening. Read how automating cellular assays can potentially reduce the cost, labour and timelines for drug discovery programmes

Download our #elrigdd24 poster on DepExML, our explainable ML pipeline for identifying predictive biomarkers from dependency datasets, which generates actionable insights into cancer biology & opportunities for potential first-in-class drug development

Read our @awscloud Customer Success story to learn more about the work we’re doing together to reimagine drug discovery, through innovative Design-Make-Test-Learn cycles, integrating generative AI drug design and robotic lab automation

Download our #ASBMR2024 poster with the Millán Lab & @rallybio, showing for the first time that ENPP1 is a druggable target for late-onset HPP. We're currently developing an ENPP1i with improved properties compared with REV101 to address unmet need in HPP

Download our #EuroQSAR poster to learn how SALSA – our new approach to virtual chemical space exploration – enables the efficient exploration of ultra-large chemical spaces, leading to the potential identification of novel and effective therapeutics.

Don’t miss our #EuroQSAR presentations next week! Our CTO @johnpoverington is giving a plenary lecture on emerging AI approaches to drug discovery & we’re presenting posters on drug-induced liver injury models & scalable active learning over synthon space 

September is #BloodCancerAwarenessMonth – a time to highlight the urgent need to deliver new treatments to blood cancer patients. We’re harnessing our AI –driven platform to tackle some of the hardest-to-treat blood cancers by targeting the underlying disease drivers. #AI

Read our @RSC_BMCS #NTGH24 poster to learn more about how we’re using novel AI-designed bispecifics to tackle malaria - hitting two targets simultaneously to potentially prevent resistance emerging. #AI #DrugDiscovery #Malaria

Read our #EUROTOX2024 poster to learn about our drug-induced liver injury models, developed with more DILI-relevant features and endpoints, for improved early estimation of DILI in potential drug candidates and to improve drug safety and attrition